A direct comparison of tirzepatide (Zepbound) and semaglutide (Ozempic) on weight loss, glycemic control, and cardiovascular outcomes, drawing on SURMOUNT-1, SUSTAIN-7, SURPASS trials, and indirect comparison data.
A clinical comparison of dapagliflozin (Farxiga) vs metformin on cost, access, efficacy, and safety, with trial data, guideline quotes, and a decision framework for prescribers and patients.
A clinical comparison of metformin and insulin glargine (Lantus) on cost, access, efficacy, and safety, with real trial data, pricing benchmarks, and prescribing guidance.
A clinical comparison of Cialis (tadalafil) and Viagra (sildenafil) covering onset, duration, dosing, side effects, and which PDE5 inhibitor fits your lifestyle best.
A detailed clinical comparison of tadalafil generic vs vardenafil side effects, dosing, drug interactions, and which PDE5 inhibitor fits different patient profiles. prepared by the HealthRX.com Editorial Team.
A detailed clinical comparison of enclomiphene citrate and Jatenzo (oral testosterone undecanoate) for male hypogonadism, covering trial data, testosterone restoration, fertility impact, safety profiles, and how to choose between them.
A clinical comparison of testosterone cypionate and enclomiphene citrate for male hypogonadism, covering efficacy, fertility impact, and how to switch safely between them.
A detailed clinical comparison of testosterone cypionate (injectable) and Jatenzo (oral testosterone undecanoate) for men's TRT, covering efficacy, dosing, safety, and how to choose between them.
A clinical comparison of testosterone cypionate injections and Jatenzo oral testosterone undecanoate, including how to switch safely between them, efficacy data, and dosing guidance.
A clinical comparison of CJC-1295 (modified GRF) and MK-677 (ibutamoren) covering mechanism, GH/IGF-1 output, body composition, safety, and how to choose between them.
A detailed clinical comparison of CJC-1295 (modified GRF) and tesamorelin (Egrifta) covering mechanism, evidence, cost, insurance access, and how to choose between them.
A detailed clinical comparison of ipamorelin acetate and CJC-1295 modified GRF side-effect profiles, dosing, mechanisms, and use cases, reviewed by board-certified physicians.
A clinical comparison of ipamorelin acetate and MK-677 (ibutamoren) covering mechanism, GH/IGF-1 output, side-effect profiles, and how to choose between them based on published trial data.
A clinical comparison of sermorelin acetate and CJC-1295 modified GRF side-effect profiles, mechanisms, dosing, and which peptide suits which patient. prepared by the HealthRX.com Editorial Team.
A clinical comparison of sermorelin acetate vs tesamorelin (Egrifta) covering mechanism, trial data, FDA approval status, dosing, and which peptide fits which patient.
A clinical comparison of PT-141 (bremelanotide) and AOD-9604 (HGH fragment 176-191) side-effect profiles, mechanisms, dosing, and which peptide fits which patient goal.
A detailed, evidence-based comparison of PT-141 (bremelanotide) and MOTS-c side-effect profiles, mechanisms, dosing, and clinical use cases, prepared by the HealthRX.com Editorial Team.
A clinical comparison of thymosin alpha-1 (thymalfasin) and epitalon tetrapeptide side-effect profiles, mechanisms, dosing, and evidence base. prepared by the HealthRX.com Editorial Team.
A clinical comparison of dutasteride (Avodart) and isotretinoin (Accutane) side-effect profiles, covering sexual health, teratogenicity, liver function, mental health, and more, prepared by the HealthRX.com Editorial Team.
A clinical comparison of finasteride and oral minoxidil for androgenetic alopecia, including how to switch between them safely, with trial data, dosing tables, and guidance.
A detailed clinical comparison of oral minoxidil and dutasteride (Avodart) for androgenetic alopecia, covering mechanism, trial data, dosing, side effects, and when to combine both.
A clinical comparison of topical minoxidil 5% and isotretinoin (Accutane) covering indications, cost, access barriers, safety, and how to choose between them.
No head-to-head trial exists, but data suggest lemborexant may edge out suvorexant on next-morning alertness and sleep onset speed. See dosing and approval details.
A direct cost, access, and clinical comparison of Ambien (zolpidem) and Dayvigo (lemborexant), including trial data, insurance coverage, DEA scheduling, and which drug fits which patient.
A comparison of oral estradiol and vaginal estradiol, mechanisms, absorption, systemic effects, risks, and a practical switching protocol for menopausal women.
Compare flibanserin (Addyi) and bremelanotide (Vyleesi) side-effect profiles, clinical trial data, dosing, contraindications, and which drug may suit different patients with HSDD.
A guide to the most common conditions that co-occur with established cardiovascular disease, how they interact, and what the evidence says about managing them together.
Evidence-based nutrition and lifestyle protocols for adults with established cardiovascular disease, including post-MI, stroke, PAD, and symptomatic CAD. Covers dietary patterns, physical activity targets, weight management, and GLP-1 therapy based on current AHA, ADA, and ACC guidelines.
A overview of male hypogonadism prevalence worldwide, secular trends, risk factors, and what the latest epidemiological data mean for diagnosis and treatment.
Evidence-based nutrition and lifestyle protocols for managing menopause-related weight gain, covering dietary strategies, exercise prescriptions, HRT interactions, and GLP-1 options. prepared by the HealthRX.com Editorial Team.
A guide to how menopause-related weight gain affects Black, Hispanic, Asian, and white women differently, with primary epidemiology, guideline recommendations, and treatment considerations by race and ethnicity.
A guide to identifying, evaluating, and enrolling in obesity clinical trials. Covers eligibility criteria, major active trials, GLP-1 and combination therapies, and step-by-step enrollment guidance for adults with BMI ≥30.
AACE, ADA, and Endocrine Society allow obesity drugs at BMI ≥30, or BMI ≥27 with a comorbidity. See how guidelines compare on thresholds and treatment eligibility.
A head-to-head comparison of PCOS diagnosis and treatment guidelines from the ADA, AACE, Endocrine Society, and the 2023 International Evidence-Based Guideline, with dosing, drug names, and cited trials.
A head-to-head comparison of prediabetes diagnostic thresholds, treatment targets, and pharmacotherapy recommendations from ADA, AACE, the Endocrine Society, and USPSTF, with primary-source citations and clinical decision guidance.
Secondary hypogonadism is frequently overlooked or confused with primary testicular failure, depression, or aging. Learn the red-flag lab patterns, commonly missed causes, and fertility-preserving treatment options including enclomiphene and hCG.
Secondary hypogonadism carries measurable economic costs through lost wages, healthcare utilization, and long-term comorbidities. This evidence-based review covers the financial burden on patients, payers, and society, and flags where precise figures require independent verification.
Practical guidance for caregivers and family members supporting someone with tendinopathy, including treatment options, home exercise protocols, red flags, and when to seek specialist care.
A look at the biological mechanisms researchers believe drive NAFLD/MASLD progression, including lipid overload, mitochondrial dysfunction, the gut-liver axis, and genetic risk, with an honest account of what is established versus still under investigation.
NAFLD affects roughly 38% of adults worldwide under the newer MASLD criteria. This evidence-based overview covers global prevalence data, regional variation, risk factor trends, and what the 2023 nomenclature change means for clinicians and patients.
A comprehensive clinical history of PCOS treatment from the 1930s to today, covering surgical, hormonal, metabolic, and emerging therapies, with primary-source citations throughout.
A clinical history of type 2 diabetes treatment, from early dietary restriction through metformin, sulfonylureas, TZDs, incretin-based drugs, SGLT2 inhibitors, and dual-agonist therapy, with the evidence hierarchy and open questions readers should carry into any current treatment discussion.
A deep dive into dapagliflozin's long-term cardiovascular effects, covering DAPA-HF, DECLARE-TIMI 58, DAPA-CKD, and current prescribing guidance for HFrEF, HFpEF, and CKD populations.
A week-by-week guide to what Farxiga (dapagliflozin) does in your first 30 days, covering blood sugar, weight, blood pressure, urinary side effects, and when to call your doctor.
Dapagliflozin (Farxiga) is not FDA-approved for prediabetes, but emerging trial data suggest it may reduce diabetes progression in high-risk patients. Learn what the evidence shows, how clinicians use it off-label, and what alternatives exist.
A guide to dapagliflozin (Farxiga) hair loss and skin changes, including genital mycotic infections, rash incidence from clinical trials, and what to do if symptoms appear.
A clinician-level review of how dapagliflozin (Farxiga) affects liver enzymes, hepatic steatosis, and fibrosis markers, with primary-literature citations and dosing guidance for patients with hepatic impairment.
Evidence-based guide to muscle preservation strategies for patients on Farxiga (dapagliflozin), covering the mechanistic rationale, clinical trial data, and actionable co-interventions to protect lean mass.
Dapagliflozin dosing for adults 50-64: 10 mg once daily for T2D, HFrEF, HFpEF and CKD; no age-based adjustment, but check eGFR before and during treatment.
Farxiga's core patent expires October 2026, with pediatric exclusivity possibly pushing generics to April 2027. Four ANDA filers have already challenged it.
Stop dapagliflozin 3 to 4 days before elective surgery to avoid euglycemic DKA risk. Resume once eating normally and kidney function is stable.
Dapagliflozin is contraindicated in the 2nd and 3rd trimesters due to fetal renal toxicity; insulin is the preferred option for diabetes in pregnancy.
Evidence-based guide to dapagliflozin (Farxiga) storage conditions, shelf life, and temperature stability, including what the FDA label actually requires and what happens when tablets are exposed to heat, light, or moisture.
Stopping Prolia (denosumab) without a transition plan is associated with rapid bone loss and reports of multiple vertebral fractures within roughly a year. This guide explains the rebound mechanism, what the evidence does and does not establish, and the bridging decisions clinicians and patients face.
Everything clinicians and patients need to know about denosumab (Prolia) storage temperatures, shelf life, stability data, cold-chain management, and what to do when a dose has been mishandled.
Evidence-based natural remedies and lifestyle treatments for PCOS, including diet, exercise, inositol, berberine, and when to consider medications. prepared by the HealthRX.com Editorial Team.
Peptide fatigue is real. Learn why GLP-1 and peptide therapies drain B12, sodium, potassium, and magnesium, and what doses actually fix it, backed by clinical evidence.
A deep dive into the evidence for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) improving menopause-related brain fog, memory, and cognitive function, including mechanisms, trial data, and clinical guidance.
Testosterone is not just a male hormone. Learn how it affects libido, energy, bone density, and mood in women, what happens during menopause, and what the evidence says about testosterone therapy for women.
A clinical deep-dive into how dulaglutide (Trulicity) changes appetite, food cravings, and eating behavior in type 2 diabetes. Includes trial data, mechanism, dose effects, and practical management.